


MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Acquisition Bell Hospital, LLC d/b/a Bell Hospital</p> <p>2. 901 Lakeshore Dr. Ishpeming, MI 49849</p>	<p>In accordance with letter dated December 27, 2021,</p>	<p>4. Expiration Date: February 29, 2024</p>	
	<p>3. License No.: 21-02037-03 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-13856 Reference No.:</p>	
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 2 curies total</p>	<p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. For any use permitted by 10 CFR 35.300.</p>



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 21-02037-03

Docket or Reference No.:
030-13856

Amendment No. 23

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at 901 Lakeshore Dr., Ishpeming, Michigan, 49849.
11. The Radiation Safety Officer (RSO) for this license is Zachary Charles Smith, M.D.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized User (M.D., D.O., etc.)</u> | <u>Material and Use</u> |
|---|---|
| Todd K. Bostwick, M.D. | 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 |
| Zachary Charles Smith, M.D. | 10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131) |
| Niksa Vlastic, M.D. | 10 CFR 35.100, 10 CFR 35.200 |
| Raymond A. Wood Jr., D.O. | 10 CFR 35.200 |
13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated November 18, 2013 (ML13323B494)
- B. Letter dated December 16, 2013 (ML13352A410)
- C. Letter dated August 28, 2018 (ML18241A254)

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 21-02037-03

Docket or Reference No.:
030-13856

Amendment No. 23

- D. Letter dated September 20, 2018 (ML18290A546)
- E. Letter dated November 16, 2018 (ML18323A250)
- F. Letter dated March 16, 2022 (ML22097A099)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: April 7, 2022

By: _____

Magdalena R. Gryglak
Region 3